Company Overview
Collegium Pharmaceutical, Inc. operates as a specialty pharmaceutical entity dedicated to the development and commercialization of medicines specifically designed for pain management. The company functions within the broader healthcare sector, more narrowly defined by its industry classification as a Drug Manufacturer specializing in Specialty & Generic products. This operational focus allows the firm to target specific therapeutic needs within the central nervous system, exemplified by its portfolio asset Jornay PM, a central nervous system stimulant prescription medicine containing methylphenidate HCl. In terms of scale, the company commands a market capitalization of $1.06B and generates annual revenue of $780.57M while employing a workforce of 423 individuals. These financial metrics indicate that Collegium holds a significant position in the specialty drug market, possessing substantial revenue generation capabilities that support its R&D and commercialization efforts relative to its employee base.
Financial Health
The company reports revenue of $780.57M for the trailing twelve months, with net income standing at $62.87M and EBITDA reaching $419.16M. The substantial gap between the $780.57M revenue and the $62.87M net income reveals a cost structure where operating expenses, including cost of goods sold and overhead, consume a significant portion of total sales before arriving at the bottom line. However, the EBITDA figure of $419.16M suggests robust operational cash generation before interest, taxes, depreciation, and amortization. The company demonstrates strong financial flexibility with free cash flow of $321.54M, which provides ample liquidity to fund ongoing operations, repay debt, or pursue strategic acquisitions without immediate reliance on external financing. Profitability is highlighted by three distinct margins: a gross margin of 88.5%, an operating margin of 30.0%, and a profit margin of 8.1%. The 88.5% gross margin indicates high pricing power and low direct production costs typical of specialty pharmaceuticals, while the 30.0% operating margin reflects efficient management of selling, general, and administrative expenses, and the 8.1% profit margin accounts for the impact of interest and other corporate-level costs. Regarding leverage, the company holds $386.68M in cash against $936.43M in total debt, resulting in a debt-to-equity ratio of 310.41, which indicates a highly leveraged balance sheet structure. Despite this leverage, the current ratio of 1.57 suggests that the company maintains adequate short-term liquidity to cover its obligations as they come due. Finally, the Return on Equity stands at 23.7% and the Return on Assets is 7.3%, metrics that reveal management is effectively utilizing shareholder capital and total assets to generate returns, particularly given the high leverage environment.
Valuation Assessment
The stock carries a P/E Ratio of 19.21 on a trailing twelve-month basis compared to a Forward P/E of 5.20. This significant discrepancy between the trailing and forward multiples implies that the market expects earnings to increase substantially in the future, driving the valuation multiple down from current levels to anticipated levels. The price-to-book ratio is recorded at 3.49, indicating that the market values the company at a premium of 249% over its net book value, likely due to the intangible value of its patent portfolio and proprietary formulations. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.35 and an EV/EBITDA of 3.83, suggesting the company trades at a moderate multiple relative to its sales and enterprise earnings power. In terms of trading range, the 52-week high is $50.79 and the 52-week low is $23.23. Without a specific current price provided in the facts, the valuation context is defined by this volatility band where the stock has demonstrated significant price discovery over the last year. The stock exhibits a Beta of 0.68, which means its price volatility is historically lower than that of the broader market, suggesting it may be less sensitive to general market fluctuations than the average large-cap stock.
Growth & Income
Revenue growth stands at 12.9% year-over-year, while earnings growth is recorded at 31.5% year-over-year. Earnings are growing at a rate significantly faster than revenue, which implies improved operational efficiency, potential cost savings, or pricing power that is translating into disproportionate bottom-line growth. The company does not currently pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Because the payout ratio is zero, the company retains all of its net income, reinvesting earnings directly into research and development, commercialization, or debt reduction rather than distributing cash to shareholders. This reinvestment strategy is consistent with a growth-phase specialty pharmaceutical company that prioritizes expanding its therapeutic portfolio over immediate income generation. The overall growth and income profile is characterized by robust double-digit revenue expansion and accelerating earnings growth, funded by strong free cash flow but without current reliance on dividend income for investors.